DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avodart (Dutasteride) - Summary

 
 



AVODART SUMMARY

AVODART®
(dutasteride)
Soft Gelatin Capsules

AVODART (dutasteride) is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5(alpha)-reductase (5AR), an intracellular enzyme that converts testosterone to 5(alpha)-dihydrotestosterone (DHT).

AVODART is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to:

  • Improve symptoms
  • Reduce the risk of acute urinary retention
  • Reduce the risk of the need for BPH-related surgery


See all Avodart indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Avodart (Dutasteride)

Benign Prostatic Hyperplasia
Source: MedicineNet Overactive Bladder Specialty [2013.12.11]
Title: Benign Prostatic Hyperplasia
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/11/2013 12:00:00 AM

Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Source: MedicineNet Prostatitis Specialty [2012.02.29]
Title: Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Category: MedicineNet Quiz
Created: 2/7/2012 3:29:00 PM
Last Editorial Review: 2/29/2012 6:25:09 PM

more news >>

Published Studies Related to Avodart (Dutasteride)

Efficacy and safety of dutasteride in chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. [2012.01.01]
Background: Dutasteride is a dual inhibitor of type I and type II 5alpha-reductases and provides nearly complete suppression of dihydrotestosterone, which plays a key role in the aetiology and development of benign prostatic hyperplasia (BPH). Most knowledge about the efficacy and safety of dutasteride in BPH derives from three pivotal phase III studies conducted primarily in Caucasian populations...

Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. [2011.10]
PURPOSE: Men at risk for prostate cancer may concurrently experience chronic prostatitis or pelvic pain. We evaluated the effect of dutasteride on prostatitis-like symptoms in the REDUCE study population... CONCLUSIONS: Long-term dutasteride therapy resulted in improvement in prostatitis related symptoms in older men with an increased prostate specific antigen. Copyright (c) 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. [2011.09]
OBJECTIVE: To investigate the effect of dutasteride versus placebo on the symptoms and associated complications of male lower urinary tract symptoms and benign prostatic hyperplasia (BPH) across a range of prostate volumes and BPH symptoms in men evaluated for prostate cancer risk reduction in the 4-year REduction by DUtasteride of prostate Cancer Events (REDUCE) trial... CONCLUSION: During the 4-year study, dutasteride was associated with a decreased risk of BPH progression in men with mild-to-moderate symptoms and normal or enlarged prostates. Copyright (c) 2011 Elsevier Inc. All rights reserved.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). [2011.08]
OBJECTIVE: * To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months... CONCLUSION: * Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Q(max) and urinary symptoms associated with BPH in men with an enlarged prostate. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.

Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. [2011.07]
PURPOSE: Benign prostatic hyperplasia and hypogonadism are common disorders in aging men. There is concern that androgen replacement in older men may increase prostate size and symptoms of benign prostatic hyperplasia. We examined whether combining dutasteride, which inhibits testosterone to dihydrotestosterone conversion, with testosterone treatment in older hypogonadal men with benign prostatic hyperplasia reduces androgenic stimulation of the prostate compared to testosterone alone... CONCLUSIONS: Combined treatment with testosterone plus dutasteride reduces prostate volume and prostate specific antigen compared to testosterone only. Coadministration of a 5alpha-reductase inhibitor with testosterone appears to spare the prostate from androgenic stimulation during testosterone replacement in older, hypogonadal men with symptomatic benign prostatic hyperplasia. Copyright (c) 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

more studies >>

Clinical Trials Related to Avodart (Dutasteride)

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride [Completed]
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride

Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer [Recruiting]
This is a study of men who have undergone a standard 10 or more core biopsy for detection of prostate cancer and determined to have prostate cancer Gleason score ≤ 7 (low to moderate risk 2-7). Of these men, one arm of a two arm randomized group will be administered a treatment regime of Dutasteride versus the control group who receive standard of care, prior to mapping biopsy. This proposal aims at studying the apparent effect of the use of Dutasteride (3 months) on initial tumor volume (at diagnosis) in men with low volume cancer before undergoing 3D mapping biopsy.

Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation [Recruiting]
Avodart (dutasteride) reduces the male hormone (DHT) that leads to prostate growth and stimulates cancerous growth. Avodart is currently approved by the FDA to treat men with symptoms of an enlarged prostate. Avodart works by reducing DHT and prostate size; therefore, the drug may be useful in improving lower urinary tract symptoms (LUTS) such as frequency, urgency, weak stream, and urination difficulty (dysuria), among others, in men with prostate cancer. Avodart may be effective in men with prostate cancer who are being treated with hormonal therapy with one injection of Zolodex (goserelin) followed one month later with a trans-urethral incision of the prostate (TUIP), and three months after that, seed implantation (SI) of the prostate.

The purpose of this study is to test whether Avodart (dutasteride) is effective on LUTS and dysuria in men with localized prostate cancer being treated with single-dose goserelin, TUIP, and interval SI.

AVODART� Alopecia Post-marketing Surveillance (PMS) [Recruiting]

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia [Recruiting]
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

more trials >>

Reports of Suspected Avodart (Dutasteride) Side Effects

Drug Ineffective (34)Erectile Dysfunction (20)Gynaecomastia (18)Dizziness (16)Prostate Cancer (16)Prostatic Specific Antigen Increased (16)Breast Tenderness (15)Breast Enlargement (14)Product Quality Issue (14)Pruritus (13)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Avodart has an overall score of 7.50. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
 

Avodart review by 35 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Alopecia
Dosage & duration:   .5mg taken daily for the period of 3 years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   Hair maintainance. Without finasteried or dutasteride patient experienced prickly heat on scalp. With treament, the prickly heat stopped. Had previously taken finasteride and hair had regrown to some extent.
Side effects:   Erections were less frequent and not as firm. Patient seemed to think that his personality was somewhat affected as well, becoming more timid.
Comments:   Take one pill daily in the morning. Seldom skipped dosage.

 

Avodart review by 37 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   hair loss
Dosage & duration:   0.5 mg taken 5 x per week for the period of 4 yrs +
Other conditions:   None
Other drugs taken:   Minoxidil
  
Reported Results
Benefits:   The treatment stopped hair loss and caused some regrowth. Some loss of effectiveness (I beieve due to worsening of underlying condition), but adding a topical solution corrected this.
Side effects:   Difficult to know. May have been slight reduction in libido, and occasional mild depression/anxiety, but not sure about these.
Comments:   0.5mg taken 5 x per week in the morning. Started taking avodart but then moved onto generic ('Dutas') with no change in effectiveness.

See all Avodart reviews / ratings >>

Page last updated: 2013-12-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012